Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer

Basit Öğe Kaydı
dc.contributor.authorKefeli, Umut
dc.contributor.authorArslan, Çağatay
dc.contributor.authorYıldırım, Mahmut Emre
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorKarabulut, Bülent
dc.contributor.authorÇubukçu, Erdem
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorYalçın, Şuayib
dc.contributor.authorTürk, Hacı Mehmet
dc.contributor.authorBilir, Cemil
dc.contributor.authorKaraca, Mustafa
dc.contributor.authorArtaç, Mehmet
dc.contributor.authorŞendur, Mehmet Nahit
dc.contributor.authorAlacacıoğlu, Ahmet
dc.contributor.authorTanrıkulu Şimşek, Eda
dc.contributor.authorDane, Faysal
dc.contributor.authorBilici, Ahmet
dc.contributor.authorÇevik, Duygu
dc.contributor.authorGümüş, Mahmut
dc.date.accessioned2021-12-06T12:08:06Z
dc.date.available2021-12-06T12:08:06Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi
dc.description.abstractBackground: Efficacy of anti-angiogenic and anti-EGFR agents has been demonstrated metastatic colorectal cancer (mCRC). Real-world evidence is especially important to detect the findings of patients outside of clinical trials. It complements together with clinical trials. However, there are a few studies that evaluated these treatments with biologics in the real-world setting. Recognizing the change that has occurred over the years will also shed light on future approaches. Therefore, we aimed to investigate the real-world data of patients with RAS-wild type mCRC. Methods: Medical records from 28 centers were collected for patients diagnosed with RAS wild-type mCRC between January 2016 and April 2019 and were included into the study. Histopathological, molecular and clinical characteristics of the patients were recorded. The treatment duration, response rate, progression-free survival and safety results were determined. Also, changes over the years were compared. Patients were compared according to the first-line biological treatments as anti-EGFR group (Group A and B) (panitumumab and cetuximab) and anti-VEGF group (group C).
dc.description.sponsorshipAmgen Ilac Tic Ltd Sti, Turkeyen_US
dc.identifier.citationKefeli, U., Arslan, Ç., Yıldırım, M. E., Işıkdoğan, A., Karadurmuş, N., Karabulut, B. ... Gümüş, M. (2021). Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer. Journal of Clinical Oncology. https://dx.doi.org/10.1200/JCO.2021.39.15_suppl.e15561
dc.identifier.doi10.1200/JCO.2021.39.15_suppl.e15561
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue15
dc.identifier.urihttps://dx.doi.org/10.1200/JCO.2021.39.15_suppl.e15561
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8619
dc.identifier.volume39
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectMetastatic Colorectal Cancer
dc.subjectTreatment Outcomes
dc.subjectONCO-colon Turkey
dc.titleReal-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer
dc.typeConference Object

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Bildiri Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu